Kza, page-71

Sept and Nov were explosive SP months for Kazia last year.
I expect similar this year with KEY inflection points to share price:
* Any positive data from the current trials (4 due) by EOY.
* Any partnerships for Paxalisib / Cantrixil
* Any start of new trials ~ GBM Agile / Cantrixil
* Any news pertaining to DIPG specifically after obtaining PRDD.
* Any submission of FDA application / approval
Don't forget; FDA application and or approval can come at ANY time.
Know what you have / Know why you have it